Longer time to PSA failure is thought to be desirable as it may be indicative of time to castrationresistant prostate cancer (CRPC) and may delay initiation of second-line therapy, which includes ...

FIRMAGON (degarelix injection) 80mg and 120mg vials of powder for reconstitution by Ferring Ferring Pharmaceuticals announced the FDA has approved the trade name Firmagon (degarelix injection) for its ...

Please provide your email address to receive an email when new articles are posted on . Men with prostate cancer assigned to degarelix had similar incidence of arrhythmia and less incidence of ...

CS21 was a three-arm, randomized (1:1:1), open-label, parallel-group Phase III trial of 12 months' duration incorporating adult male patients with histologically confirmed adenocarcinoma of the ...

ORLANDO—Prostate cancer (PCa) patients treated with degarelix have a lower risk of PSA failure or death compared with those treated with leuprolide, according to the findings of a long-term study. The ...

FDA has approved the trade name Firmagon for degarelix for injection, a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of advanced prostate cancer. “This ...

Firmagon is a brand-name medication that contains the active ingredient degaralix. It’s a synthetic hormone blocker that reduces testosterone production, and it’s approved to treat advanced prostate ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/hgtc2g/firmagon) has announced the addition of GlobalData's new report ...

Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group Premenopausal women with ...

Degarelix is a new hormonal therapy from the GnRH receptor blocker class of agents that immediately blocks the GnRH receptor and achieves fast testosterone suppression without an initial surge. In the ...